August 18, 2026 08:06 am (IST)
Follow us:
Migraine treatment injection from Dr Reddy's Lab now available in the US
Hyderabad/Princeton-NJ, Apr 19 (IBNS) Promius Pharma LLC, a subsidiary of Dr. Reddy's Laboratories Ltd, has informed on Tuesday that its ZEMBRACE SymTouch (sumatriptan injection) 3 mg, which was approved by the FDA in January 2016 for the acute treatment of migraine with or without aura in adults, is now commercially available in the U.S.
The company said that ZEMBRACE SymTouch is a pre filled, low-dose, ready-to-use, 2-step autoinjector containing 3 mg of sumatriptan, a selective 5-HT1B/ID receptor agonist. Because ZEMBRACE SymTouch is a subcutaneous injection, it may lead to rapid relief of migraine.
Migraineurs often have more than one kind of attack. Different types of medications can be used to treat different types of attacks.
According to Roger Cady, MD, Associate Executive Chairman of the National Headache Foundation “ZEMBRACE SymTouch is a welcome addition to the toolkit for acute treatment of migraine. This 3-mg, easy to-use subcutaneous injection of sumatriptan may be desired by many migraine patients who need a medication that can rapidly treat migraine attacks. Also, the 3-mg dose allows for up to 4 doses of ZEMBRACE SymTouch in a 24-hour period, thus allowing dosing flexibility for patients.”
ZEMBRACE SymTouch is available as a box of 4 autoinjectors.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
Latest Headlines
BPCL flags off first extreme weather grade diesel rake from Bina Refinery to power Indian Army’s high-altitude operations
Mon, Aug 17 2026
Chief Economic Adviser backs E10 option for older vehicles as E20 fuel transition sparks debate
Mon, Aug 17 2026
L&T secures ultra-mega order for strategic offshore development project in Middle East
Mon, Aug 17 2026
Mahindra launches BLAZO i-TRK: All details inside
Sun, Aug 16 2026
Reliance Industries, Rolls-Royce join hands to explore indigenous engine for India’s AMCA fighter
Sat, Aug 15 2026
BSNL’s Independence Day gift: Re 1 Recharge, 412-Day Plan and 500 Free TV Channels. Check now
Sat, Aug 15 2026
Emami’s big snack bet: ₹750 crore investment, new WeMe brand targets ₹1,000 crore in 3-5 years
Sat, Aug 15 2026